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Original Article
Angiopoietin-1 Mimetic Peptide Promotes
Neuroprotection after Stroke in Type 1
Diabetic Rats
Poornima Venkat1, Tao Yan1,2,3, Michael Chopp1,4, Alex Zacharek1,
Ruizhuo Ning1,5, Paul Van Slyke6, Daniel Dumont7,
Julie Landschoot-Ward1, Linlin Liang1,8, and Jieli Chen1
Abstract
Angiopoietin-1 (Ang1) mediates vascular maturation and immune response. Diabetes decreases Ang1 expression and disrupts
Ang1/Tie2 signaling activity. Vasculotide is an Ang1 mimetic peptide, and has anti-inflammatory effects. In this study, we test
the hypothesis that vasculotide treatment induces neuroprotection and decreases inflammation after stroke in type 1 diabetic
(T1DM) rats. T1DM rats were subjected to embolic middle cerebral artery occlusion (MCAo) and treated with: 1) phosphate
buffered saline (PBS); 2) vasculotide (3mg/kg, i.p. injection) administered half an hour prior to MCAo and at 8 and 24 hours after
MCAo. Rats were sacrificed at 48 h after MCAo. Neurological function, infarct volume, hemorrhage, blood brain barrier (BBB)
permeability and neuroinflammation were measured. Vasculotide treatment of T1DM-MCAo rats significantly improves
functional outcome, decreases infarct volume and BBB permeability, but does not decrease brain hemorrhagic transformation
compared with PBS-treated T1DM-MCAo rats. In the ischemic brain, Vasculotide treatment significantly decreases apoptosis,
number of cleaved-caspase-3 positive cells, the expression of monocyte chemotactic protein-1 (MCP-1) and tumor necrosis
factor (TNF-a). Western blot analysis shows that vasculotide significantly decreases expression of receptor for advanced
glycation end products (RAGE), MCP-1 and TNF-a in the ischemic brain compared with T1DM-MCAo rats. Vasculotide
treatment in cultured primary cortical neurons (PCN) significantly decreases TLR4 expression compared with control.
Decreased neuroinflammation and reduced BBB leakage may contribute, at least in part, to vasculotide-induced neuropro-
tective effects after stroke in T1DM rats.
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Introduction
Ischemic stroke is a prominent cause of death and long-term
disability in adults, and is often accompanied by hefty medical
and social costs. Diabetesmellitus is a chronic, lifelong, global
health concern, that elevates multifold the risk of ischemic
stroke1. Co-morbidity of stroke and diabetes worsens prog-
nosis, and patients are prone to developing vascular disorders
and stroke recurrence2,3. In addition to inducing metabolic
abnormalities, diabetes induces extensive microvascular and
macrovascular damage, which contributes to higher morbidity
after stroke2,3. Diabetes decreases Angiopoietin-1 (Ang1)
expression, disrupts Ang1/Tie2 signaling activity, and impairs
Ang1-mediatedvascular remodelingand immune responses4,5.
In mice with diabetes, decreased Ang1 has been implicated to
increase blood brain barrier (BBB)disruption and brain hemor-
rhagic transformation after stroke6. Ang1 is an endothelial
growth factor, and is essential for endothelial cell survival and
function7. Ang1 is a primary physiological ligand for tyrosine
kinase, Tie2, and Ang1 mediates key steps of angiogenesis
such as migration and adhesion of endothelial cells, and vessel
maturation7,8. In the ischemic brain, Ang1 improves oxygen
and nutrition availability to ischemic tissue via enhancement of
angiogenesis and vascular development9,10.
Vasculotide is an Ang1 mimetic peptide that activates
and/or promotes Tie2 function11. An in vivo study using a
murine abdominal sepsis model has demonstrated that sys-
temic administration of vasculotide induces long-lasting
Tie2 activation, decreases mortality and exerts protection
against microvascular dysfunction12. In stroke patients, sig-
nificant reduction of plasma Ang1 level at the time of hos-
pitalization was associated with poor functional outcomes at
3 months after stroke13. In rodents subject to diabetic stroke,
exacerbated functional deficits have been attributed to a sig-
nificant reduction of Ang-1 expression and increase of
inflammatory factors in the ischemic brain, while treatments
increasing Ang1 have been associated with improved func-
tional outcome and decreased neuroinflammation in the
ischemic brain6,8,14. In a mouse stroke model, stroke treat-
ment using recombinant adenoviruses expressing Ang1 sig-
nificantly decreases BBB permeability and reduces infarct
volume14. Several studies have previously reported that there
is a differential response to stroke treatments between dia-
betic and non-diabetic subjects15,16. In this study, we inves-
tigate the effectiveness of vasculotide as a neuroprotective
agent for stroke in type 1 diabetes mellitus (T1DM) rats.
Ang1 has also been shown to exert anti-inflammatory
effects and protect endothelial cell permeability against
inflammatory factors17. Among the several up-regulated
inflammatory mediators after stroke are included monocyte
chemotactic protein-1 (MCP-1) and tumor necrosis factor-a
(TNF-a)18,19. MCP-1 is an inflammatory chemokine that is
expressed in neurons, astrocytes, and endothelial cells in
response to ischemia, and regulates the migration and infil-
tration of monocytes and macrophages to the core of injured
brain tissue18,20. TNF-a is a cytokine associated with
proinflammatory responses post stroke21,22. TNF-a expres-
sion increases significantly post stroke in the ischemic core of
experimental stroke animals, as well as in the serum and
cerebrospinal fluid of stroke patients, and correlates with
stroke severity22,23. Up regulation of TNF-a has been associ-
ated with increased BBB permeability19 and, as expected,
inhibition of TNF-a activity reduces infarct volume and
improves neurological outcome after stroke24. Therefore,
decreasing neuroinflammation after stroke is important to
promote neuroprotective effects and prevent additional dam-
age to the injured brain. In this study, we investigatedwhether
vasculotide treatment decreases proinflammatory factors and
exerts neuroprotective effects after stroke in T1DM rats.
Materials and Methods
All experiments were conducted in accordance with the stan-
dards and procedures of the American Council on Animal
Care and Institutional Animal Care and Use Committee of
Henry Ford Health System.
Diabetes induction
Streptozotocin dose dependently damages pancreatic b cells
and is used widely to induce T1DM in rodents25,26. Adult
male Wistar rats (225–250 g, 8–12 weeks old, Charles River,
San Diego, CA, USA) were given a single intraperitoneal
(i.p.) injection of Streptozotocin (60 mg/kg, Enzo, Farming-
dale, NY, USA) to induce T1DM. Rats with fasting blood
glucose >300 mg/dl at 2 weeks after Streptozotocin injection
were considered diabetic and were subjected to embolic
middle cerebral artery occlusion (MCAo).
MCAo model and experimental groups
Right embolic MCAo was performed on anesthetized T1DM
rats as previously described27. Rats were randomized to two
groups (n ¼ 7/group): 1) Phosphate buffered saline (PBS)
treatment for vehicle control; 2) vasculotide treatment
(3 mg/kg, i.p. injection) initiated half an hour prior to MCAo
and at 8 and 24 h after MCAo. A battery of functional tests
was conducted and rats were sacrificed at 48 h after MCAo
for immunostaining quantification analysis. The dose was
estimated based on prior publications that have demonstrated
that administering 500ng/mice via i.p. injection exerts
protection against murine models of severe influenza28.
Neurological functional tests
All functional testswere performed by an investigator blinded
to the experimental groups. Neurological functional outcome
was evaluated using a battery of functional tests including
foot-fault, and a modified neurological severity score
(mNSS) evaluation before MCAo, and at 2, 24 and 48 h after
MCAo. Briefly, mNSS is a composite of motor, sensory, bal-
ance and reflex tests29. The absence of a tested reflex or
abnormal response is scored as 1 point; neurological function
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is scored between 0 and 18, with 0 indicating no deficits and
18 indicating maximum deficits. In the foot-fault test30, ani-
mals are placed on an elevated grid floor (45 cm 30 cm), 2.5
cm higher than a solid base floor, with 2.5 cm  2.5 cm
diameter grid spacing. While the animal is moving on the
wire frame using their paws, a fall or slip through a grid
opening due to an inaccurate forelimb placement is recorded
as a foot-fault. Data are presented as the percentage of foot-
faults of the left paw over a 100 forelimb movements.
Immunohistochemistry
Transcardial perfusion with saline followed by perfusion and
immersion in 4% paraformaldehyde was used to fix brains.
The brains were then embedded in paraffin and a standard
block was obtained from the center of the lesion (bregma –1
mm to þ1 mm). A series of 6 mm thick sections were cut
from the block. Seven hematoxylin and eosin (H&E) stained
coronal sections of tissue were used for lesion volume cal-
culation and presented as a percentage of lesion compared
with the contralateral hemisphere. Brain hemorrhage was
measured using H&E staining under light microscopy. The
percentage areas of petechial and gross hemorrhage were
measured in each histological section and summed.
Brain coronal tissue sections were prepared and antibody
against TNF-a (1:200; Abcam, Cambridge, MA, USA),MCP-
1 (1:100, Abcam, Cambridge, MA, USA) and Cleaved
Caspase-3 (1:200, Cell Signaling Technology, Danvers,
MA, USA) were employed. For measuring apoptosis, terminal
deoxynucleotidyl transferase–mediated dUTP nick-end label-
ing (TUNEL) was performed using a commercial kit (Apop-
tag Kit, S7100, Chemicon, Temecula, CA, USA). Control
experiments consisted of staining brain coronal tissue sections
as outlined above, but non-immune serum was substituted for
the primary antibody.
Quantification analysis
An investigator blinded to the experimental groups per-
formed all immunostaining quantification analysis. For quan-
titative measurements, five slides from each brain, with each
slide containing six to eight fields from the ischemic lesion
were digitized under a 20 objective (Olympus BX40) using
a 3-CCD color video camera (DXC-970MD, Sony, Tokyo,
Japan) interfaced with an MCID image analysis system
(Imaging Research, St. Catharines, ON, Canada). The posi-
tive areas or positive cell numbers were then measured.
BBB disruption quantification measurements
To measure BBB leakage, an additional set (n ¼ 4/group) of
T1DM-MCAo rats treated with PBS or vasculotide were
injected intravenously with 2% Evans blue dye 4 h before
euthanasia (48 h after MCAO). Evans blue dye fluorescence
intensity was measured using a microplate fluorescence
reader (excitation 620 nm and emission 680 nm).
Western blot assay
Protein was isolated from samples using Trizol (Invitrogen,
Carlsbad, CA, USA) following standard protocol. Protein
concentration was measured using the BCA kit (Thermo
Scientific, Waltham, MA, USA). Antibodies against MCP-
1 (1:1000, Abcam, Cambridge, MA, USA), RAGE (receptor
for advanced glycation end products, 1:500, R&D Systems,
Minneapolis, MN, USA), TNF-a (1:1000, Abcam, Cam-
bridge, MA, USA) and anti-b-actin (1:10000; Abcam, Cam-
bridge, MA, USA) were employed for western blot
measurements.
Primary cortical neuron cell culture and experimental
groups
Primary cortical neurons (PCN) were harvested from
embryonic day-18 Wistar rats (Charles River, Wilmington,
MA, USA). Cultures were prepared according to a previously
described procedure31,32. Briefly, embryos were removed, and
the cerebral cortex dissected and dissociated by a combination
of Ca2þ- and Mg2þ-free Hanks balance salt solution (HBSS)
containing 0.125% trypsin digestion for 15min, thenmechani-
cally triturated around 20 times. After the cells were harvested
they were initially plated in DMEM with 5% fetal bovine
serum (FBS) for 4 h, and then cultured in a medium consisting
of neurobasal (Invitrogen, Carlsbad, CA, USA), 2% B-27
(Invitrogen, Carlsbad, CA, USA), 2 mM GlutaMax, and 1%
antibiotic-antimycotic31,32 for a week prior to oxygen and glu-
cose deprivation (OGD). The triturated cells were passed
through a 40 mm cell strainer and counted to obtain a concen-
tration of 3 107 cells/ml. Cells were then exposed toOGD for
2 h. Following OGD, PCN cells were cultured with high glu-
cose (37.5 mM) and divided into two groups: 1) control group
and 2) 10 nM vasculotide-treated group (n ¼ 4/group). Cells
were treated overnight and, on the following day, RNA was
isolated with TRIzol following a standard protocol.
Real time polymerase chain reaction assay
Total RNA was isolated with TRIzol (Invitrogen, Carlsbad,
CA, USA), following standard protocol. Total RNA (2 mg)
was used to make cDNA (complementary DNA) using the
M-MLV (Invitrogen) standard protocol. A 2 ml aliquot of
this cDNA was then used to run a quantitative polymerase
chain reaction (PCR) using the SYBR Green real-time PCR
method. Quantitative PCR was performed on a ViiA 7 PCR
instrument (Applied Biosystems, Foster City, CA, USA)
using 3-stage program parameters provided by the manufac-
turer, as follows; 2 min at 50C, 10 min at 95C, and then 40
cycles of 15 s at 95C and 1 min at 60C. Each sample was
tested in triplicate, and analysis of relative gene expression
was collected using the 2–DDCT method.
TLR4: Fwd: TCTAACTTCCCTCCTGAGATGG; Rev:
ACTGGCTAGAGAGCAAGAGGAA
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Statistical analysis
One-way analysis of variance (ANOVA) was used for the
evaluation of functional outcome and histology, respec-
tively. “Contrast/estimate” statement was used to test the
group difference. If an overall treatment group effect was
detected at P < 0.05, pair-wise comparisons were made. All
data are presented as mean + standard error (SE).
Results
Vasculotide treatment for stroke significantly improves
neurological functional outcome and decreases infarct
volume and BBB leakage in T1DM rats
Vasculotide treatment in T1DM-MCAo rats significantly
improves neurological functional outcome as indicated
by mNSS and foot fault test at 24 and 48 h after stroke
(Fig. 1a-b), decreases ischemic burden as indicated by
decreased infarct volume (Fig. 1c), and decreases BBB dis-
ruption as evaluated by Evans blue dye extravasation assay
(Fig. 1d) compared with PBS-treated T1DM stroke rats.
Vasculotide treatment of stroke in T1DM rats
decreases apoptosis and inflammatory factor
expression
Immunostaining quantification analysis in the ischemic
regions of brain shows that vasculotide treatment of stroke
in T1DM rats significantly decreases the number of cleaved-
caspase-3 positive cells (Fig. 2a) and TUNEL positive cells
(Fig. 2b), in comparison with PBS-treated T1DM-MCAo
rats. Based on caspase 3 activation or DNA degradation,
cleaved-caspase3 and TUNEL staining are markers of dam-
aged cells that have entered an apoptotic pathway, across all
cell types. Therefore, it is difficult to identify the cell types
that are labeled by these immunostaining in Fig. 2a-b. Vas-
culotide treatment of stroke in T1DM rats significantly
decreases the expression of MCP-1 (Fig. 2c) and TNF-a
(Fig. 2d) in comparison with PBS-treated T1DM-MCAo
rats. Western blot analysis (Fig. 3a-b) shows that vasculotide
treatment of stroke in T1DM rats significantly decreases the
expression of RAGE, MCP-1 and TNF-a in the ischemic
brain compared with PBS-treated T1DM-MCAo rats;
thereby confirming immunohistochemical findings.
Vasculotide treatment of PCN significantly decreases
inflammatory factor TLR4 expression compared with
non-treated PCN controls
To test whether vasculotide regulates PCN inflammatory
factor expression, PCN cell culture was performed.
Figure 4c shows that PCNs that were subjected to OGD and
high glucose conditions, and treated with vasculotide, exhi-
bit significantly decreased TLR-4 gene expression compared
with the non-treated control group.
Fig. 1. Vasculotide treatment improves functional outcome after stroke in T1DM rats. In T1DM stroke rats, vasculotide (VT)
treatment significantly improves neurological functional outcome as indicated by a) mNSS and b) foot-fault tests; c) decreases lesion volume;
and d) decreases BBB leakage compared with PBS-treated T1DM stroke rats.
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Discussion
In this study, we show for the first time that vasculotide
treatment of stroke in T1DM rats promotes neuroprotective
effects such as reducing infarct volume, decreasing BBB
disruption, and improving neurological functional outcome
as well as reducing neuroinflammation.
Diabetes instigates and aggravates endothelial cell dys-
function resulting in increased vascular permeability after
stroke2,33. We have employed a Streptozotocin-induced
T1DM model in rats that is well documented25,26. We have
demonstrated previously that the STZ-induced T1DMmodel
decreases cerebral vascular perfusion, decreases cerebral
artery diameter with increasing wall thickness, and increases
the number of occluded cerebral arterioles compared with
non-diabetic rats34. In addition, stroke in T1DM rats induced
worse neurological outcome, vascular dysfunction and
greater BBB leakage compared with stroke in non-diabetic
rats15,34. BBB disruption after stroke is a key event that
triggers neurovascular uncoupling and facilitates invasion
of inflammatory factors, neurotoxins, and pathogens into the
brain, contributing to adverse neurological outcome post
Fig. 2. Vasculotide treatment decreases apoptosis and neuroinflammation after stroke in T1DM rats. In T1DM stroke rats,
vasculotide (VT) treatment significantly decreases apoptosis in ischemic regions as indicated by a) cleaved-caspase 3 and b) TUNEL; and
expression of inflammatory factors such as c) MCP-1 and d) TNF-a immunostaining and quantification analysis.
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stroke in the diabetic population33,35,36. Protecting BBB
integrity has been associated with improved neurological
function after brain injury, particularly in stroke and diabetic
stroke8,37. In our study, we found that vasculotide treatment
of T1DM stroke significantly decreases infarct volume and
BBB leakage, which may contribute to improved neurologi-
cal function after stroke.
Vasculotide is a synthetic Ang1 mimetic peptide. Ang1 is
an angiogenic growth factor that activates Tie-2 to promote
migration, sprouting, and survival of endothelial cells and
recruitment of vascular smooth muscle cells and pericytes
during vascular maturation36. The effects of Ang1
overexpression in the brain include increased vascularization
and neuronal dendrite configuration, neurite outgrowth, and
neuronal differentiation38. Apart from its role in angiogenic
processes, Ang1 signaling also counteracts several inflam-
matory responses. A major gateway to the pathophysiologi-
cal mechanisms of diabetic stroke is the activation of
inflammatory responses that exert adverse effects on the
progression of tissue damage and aggravate vascular
damage39. Inflammatory processes are considered to be a
leading cause of stroke-induced brain dysfunction, and dia-
betic stroke patients suffer from worse and prolonged BBB
leakage15,33,40.
The neuroprotective effects of vasculotide in T1DM
stroke rats may be due, at least in part, to a decrease in
neuroinflammatory responses. MCP-1 has been demon-
strated to be a potent monocyte chemotactic factor in several
models of inflammation, and to promote monocyte/macro-
phage infiltration41. In patients with cardiovascular diseases
such ischemic stroke and myocardial infarction, a two-fold
increase in circulating MCP-1 levels has been reported42. In
T2DM patients, MCP-1 is significantly increased in the cir-
culation43, and is associated with diabetic complications
such as diabetic nephropathy, diabetic retinopathy, etc44.
In rats subjected to either transient or permanent MCAo,
MCP-1 expression significantly increased in the ischemic
hemisphere as early as 6 h, and peaked at 2 days after
stroke45,46. TNF-a significantly increases in neurons in the
ischemic cortex as early as 1–3 h post MCAo, peaks at 12 h,
Fig. 3. Vasculotide treatment decreases neuroinflammation after stroke in T1DM rats. Vasculotide (VT) treatment of stroke in
T1DM rats decreases the expression of inflammatory factors RAGE, MCP-1 and TNF-a in the ischemic brain tissue as measured by a)
western blot assay and b) quantification analysis.
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and remains elevated even at 5 days after stroke21. Given the
temporal profiles of TNF-a and MCP-1, which increase
early after MCAo, it is likely that they create a proinflam-
matory and hostile environment in the ischemic brain, which
exacerbates tissue damage. In experimental stroke models,
MCP-1 deficiency improves neurological functional out-
come, reduces ischemic lesion volume, decreases the accu-
mulation of phagocytic macrophages in the ischemic core
and penumbra, reduces BBB disruption, and attenuates the
expression of inflammatory factors47,48. Similarly, treating
rodents subject to experimental stroke models with either
TNF-a binding receptors or an inhibitor of TNF-a convert-
ing enzyme to block TNF-a activity, has several neuropro-
tective effects, including decreased infarction volume,
leading to improved neurological function24,49. In our study,
we found that treatment of stroke in T1DM rats with vascu-
lotide significantly attenuates the expression of MCP-1 and
TNF-a, which may be associated with vasculotide-induced
neuroprotective effects after stroke.
High mobility group box 1 (HMGB1) is an inflammatory
mediator secreted upon injury by immune cells or injured
cells, and it binds to its receptors TLR4 and RAGE. In our
previous studies, we have reported a significant increase of
HMGB1 and RAGE expression post stroke in the ischemic
brain of T1DM rats50. Proinflammatory factors such as
TLR4 and RAGE are significantly increased after diabetic
stroke and have been implicated in aggravated tissue
injury50,51. Increased RAGE expression after stroke in DM
animals has been associated with inflammation in the
ischemic brain and correlated with poor neurological
functional outcome50. Ang1 significantly decreases the
expression of inflammatory factor RAGE in cultured brain
endothelial cells8. We found that vasculotide treatment of
stroke in T1DM rats significantly decreases the expression
of inflammatory factors such as MCP-1, RAGE, and TNF-a
in the ischemic brain and TLR4 in cultured PCN subject to
high glucose and OGD conditions. Thus, vasculotide treat-
ment may exert neuroprotective effects by regulating post
stroke inflammatory responses.
Limitations
This is a proof-of-concept study in which we show that
vasculotide induces neuroprotective effects after stroke in
T1DM rats, which may, in part (directly or indirectly), be
attributed to reduction of neuroinflammation. This study
employs vasculotide as a pre-stroke treatment. To minimize
translation hurdles of therapies from pre-clinical testing to
the clinic52, future studies on post-stroke treatment with
wide therapeutic window and testing the long-term effects
of vasculotide treatment for T1DM stroke are warranted.
Causal mechanistic studies are missing and future using a
co-culture system to get insight into the mechanisms of
vasculotide-induced neuroprotective and anti-inflammatory
effects and future studies are warranted.
Conclusions
Vasculotide treatment promotes neuroprotective effects after
stroke in T1DM rats and improves neurological function
outcome compared with PBS-treated T1DM stroke rats. Pro-
tection of BBB integrity and decrease of neuroinflammatory
responses may contribute to vasculotide-induced neuropro-
tective effects observed after stroke in T1DM rats.
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